Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Ocugen is a clinical stage biopharmaceutical company focused on discovering, devel...
Ocugen is a clinical stage biopharmaceutical co...
DLH (NASDAQ:DLHC) serves federal government clients throughout the United States a...
DLH (NASDAQ:DLHC) serves federal government cli...
Agenus is an immuno-oncology company designed to deliver innovation with speed for...
Agenus is an immuno-oncology company designed t...
EpigenCare is connecting consumers with skincare companies through a direct-to-con...
EpigenCare is connecting consumers with skincar...
BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autolog...
BrainStorm (NASDAQ:BCLI) is a biotechnology com...
ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells innovative medica...
ICU Medical, Inc. (Nasdaq:ICUI) develops, manuf...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Join the National Investor Network and get the latest information with your interests in mind.